Stocks · News reference
Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.54 per share which beat the analyst consensus estimate of $0.45 by 20 percent. This is a 45.95 percent increase over earnings of $0.37 per share from the same
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.
A deepening chip rout drags the Nasdaq while Coca-Cola and Sherwin-Williams beats power the Dow; oil dives 5% on Iran diplomacy as the Fed meets.